Foamix Pharmaceuticals Second Quarter Financial Results Conference Call & Webcast Scheduled for August 9
|Conference Call & Webcast|
|Wednesday, August 9, 2017 @ 8:30 am Eastern Time|
|Replays, Available through August 23rd:|
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy.
Our clinical stage product candidates include our novel minocycline foam FMX101 for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo, and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.
In addition, we have development and license agreements relating to our technology with various pharmaceutical companies including
For more information, please visit www.foamixpharma.com.
Ilan Hadar, Country Manager & CFO Foamix Pharmaceuticals Ltd.+972-8-9316233 firstname.lastname@example.org US Investor Relations Michael Rice LifeSci Advisors, LLC646-597-6979 email@example.com